Brief: China Health Group Updates On Treatment Regimen Of COVID-19 Pneumonia Treatment Protocol
17/03/2022 01:20
March 17 (Reuters) - China Health Group Inc 8225.HK :
* ON MARCH 14, HEALTH CARE COMMISSION ADDED
PF-07321332/RITONAVIR
TO TREATMENT REGIMEN OF "COVID-19 PNEUMONIA TREATMENT PROTOCOL"
Further company coverage: 8225.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Health
See all newsBrief: China Health Group Says Court Dismisses Application To Set Aside Arbitration Award
Brief: China Health Says China Medical Group Initiated Legal Proceedings
Brief: China Health Group Says Song Xuemei Tendered Resignation As Executive Director
Brief: China Health Group Says Revenue Recognized In 1Q22 & 2Q22 Has Been Partially Adjusted During 4Q22
Brief: China Health Group Makes Application To Stock Exchange For Resumption In Trading